RUXOLITINIB PHOSPHATE | N217180 | INCYTE CORP
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 7598257 | Dec 24, 2027 | — | Yes | Yes | — | |
| 8415362 | Dec 24, 2027 | — | Yes | Yes | — | — |
| 8530485 | Dec 12, 2026 | — | — | Yes | — | — |
| 8722693 | Jun 12, 2028 | — | Yes | Yes | — | — |
| 8822481 | Jun 12, 2028 | — | — | — | — | |
| 8829013 | Jun 12, 2028 | — | — | — | — | |
| 9079912 | Dec 12, 2026 | — | — | — | — | |
| 9206187 | Dec 12, 2026 | — | — | — | — | |
| 9814722 | Dec 12, 2026 | — | — | — | — | |
| 10016429 | Jun 12, 2028 | — | — | — | — | |
| 10874616 | Nov 14, 2033 | — | — | Yes | — | — |
| 11213528 | Jun 12, 2028 | — | — | Yes | — | — |
| 11337927 | Jan 17, 2034 | — | — | — | — | |
| 11576864 | Nov 14, 2033 | — | — | — | — | |
| 11576865 | Nov 14, 2033 | — | — | Yes | — | |
| 11744832 | Dec 12, 2026 | — | — | — | — | |
| 11896717 | Nov 14, 2033 | — | — | Yes | — |
Incyte Corp received FDA approval for JAKAFI XR (ruxolitinib phosphate) as a new product formulation under NDA 217180, supplement 004.
New: New record
Incyte Corp's JAKAFI XR (ruxolitinib phosphate) extended-release formulation received FDA approval under NDA 217180, supplement 002.
New: New record
Incyte Corp added JAKAFI XR (ruxolitinib phosphate) as a new product with NDA 217180 supplement 001 to the FDA database.
New: New record
Incyte Corporation added U.S. Patent 8,822,481 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 9,079,912 to the Orange Book listing for Jakafi XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte added U.S. patent 9,206,187 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 10,016,429 to the Orange Book for JAKAFI XR (ruxolitinib phosphate).
New: New record
Incyte Corp added U.S. Patent 11,576,865 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate), NDA 217180.
New: New record
Incyte Corp added U.S. Patent 8,415,362 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) in connection with NDA 217180, Supplement 005.
New: New record
Incyte Corp added U.S. patent 10,874,616 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) for NDA 217180.
New: New record
Incyte Corp added patent 10,016,429 to the Orange Book listing for Jakafi XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 8,415,362 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. patent 9,206,187 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
INCYTE CORP listed U.S. Patent 8,415,362 in the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte added U.S. Patent 8,722,693 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte added U.S. Patent 9,079,912 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte added U.S. patent 9,814,722 to the Orange Book for Jakafi XR (ruxolitinib phosphate), listed as patent number 001 for NDA 217180.
New: New record
Incyte Corp added patent 10,016,429 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. patent 11,337,927 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 10,874,616 to the Orange Book for Jakafi XR (ruxolitinib phosphate) NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,576,865 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added patent 11,576,864 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,337,927 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) as patent number 001 for NDA 217180.
New: New record
Incyte Corp added U.S. patent 11,576,865 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) NDA 217180.
New: New record
Incyte added patent 11,744,832 to the Orange Book for Jakafi XR (ruxolitinib phosphate) NDA 217180.
New: New record
Incyte Corp added U.S. Patent 10,874,616 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
INCYTE CORP added U.S. Patent 11,896,717 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,576,865 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,576,864 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte added U.S. Patent 11,213,528 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 7,598,257 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,576,864 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) extended-release formulation.
New: New record
Incyte Corp added U.S. Patent 11,744,832 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,744,832 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,213,528 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte added U.S. Patent 8,822,481 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) NDA 217180.
New: New record
Incyte Corp added U.S. Patent 7,598,257 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) for NDA 217180.
New: New record
Incyte Corp added U.S. Patent 8,530,485 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Jakafi XR (ruxolitinib phosphate) received FDA approval as a new extended-release formulation under NDA 217180, supplement 003.
New: New record
Jakafi XR (ruxolitinib phosphate) received FDA approval as a new extended-release formulation under NDA 217180, supplemental application 005.
New: New record
Incyte Corporation added U.S. Patent 7,598,257 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added United States Patent 9,079,912 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 11,896,717 to the Orange Book for Jakafi XR (ruxolitinib phosphate).
New: New record
Incyte Corp added U.S. Patent 11,576,864 to the Orange Book for Jakafi XR (ruxolitinib phosphate) under NDA 217180, indicating patent listing for the extended-release formulation.
New: New record
Incyte Corp added US Patent 8,822,481 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corp added U.S. Patent 8,530,485 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
INCYTE CORP added U.S. Patent 9,814,722 to the Orange Book listing for JAKAFI XR (ruxolitinib phosphate) under NDA 217180.
New: New record
Incyte Corporation added U.S. Patent 8,722,693 to the Orange Book for JAKAFI XR (ruxolitinib phosphate) NDA 217180.
New: New record
Incyte Corp added US Patent 10,016,429 to the Orange Book for Jakafi XR (ruxolitinib phosphate), NDA 217180.
New: New record
Incyte added U.S. Patent 11,744,832 to the Orange Book for Jakafi XR (ruxolitinib phosphate) extended-release formulation (NDA 217180).
New: New record